Pfizer's Alopecia Drug Litfulo Shows Promising Phase 3 Results,

Pfizer Inc. reported positive results from two Phase 3 trials of LITFULO (ritlecitinib) for nonsegmental vitiligo. The trials showed significant improvements in facial and total body repigmentation compared to placebo. Pfizer plans to submit these data to global regulatory authorities, including the FDA and EMA. LITFULO is already approved for severe alopecia areata.

Pfizer sued Sun Pharmaceutical in federal court, alleging its generic versions of lung cancer drug Lorbrena infringe four patents. The patents expire between 2033 and 2038. Lorbrena had $407M in US sales in 2025, per Bloomberg. Pfizer seeks to block Sun's copies and unspecified damages.

Pfizer (PFE) reported positive Phase 3 trial results for LITFULO, a vitiligo treatment, showing significant skin repigmentation. The company plans regulatory submissions. PFE has a 6.35% dividend yield, a payout ratio of 0.71, and a GF Score of 71/100, indicating fair valuation but modest growth.

Florida sued Pfizer and its CEO, alleging deceptive marketing of the COVID-19 vaccine. The state seeks damages and an injunction, claiming Pfizer misled consumers. Pfizer denies wrongdoing, stating its claims were accurate and science-based. A 2025 grand jury found no evidence of lawbreaking by vaccine manufacturers.

Florida sued Pfizer and CEO Albert Bourla, alleging deceptive practices regarding COVID-19 vaccine safety, efficacy, and marketing. The lawsuit claims Pfizer misled consumers about risks like myocarditis and pregnancy complications, and overstated the vaccine's ability to prevent transmission. Florida seeks damages under state consumer-protection laws, while Pfizer denies wrongdoing and calls the case meritless.

Pfizer reported phase 3 trial results showing Litfulo significantly improved facial and body repigmentation in vitiligo patients after one year. The data supports its potential as a treatment for the condition.